ClinicalTrials.gg
RecruitingNCT06093724TRANSPELVUpdated Jul 22, 2025

Prospective Imaging Assessment of Perineo-pelvic Static's Evolution After Sexual Reassignment Surgery in MtF Transgender Patient, by Peno-scrotal Inversion Vaginoplasty Technique (TRANSPELV)

An interventional study of Static and dynamic perineo-pelvic MRI in Transgenderism, sponsored by University Hospital, Limoges. Recruiting at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by University Hospital, Limoges · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The research consists of adding to the usual MtF transgender patient undergoing vaginoplasty care course, static and dynamic perineo-pelvic MRI before, and at 6 and 24 months. The aim is to assess perineo-pelvic static's evolution, based on the appearance of a rectocele.

Read the detailed description

Transgender people are estimated to be about 0,3 to 1 % of general population, and MtF reassignment surgery is raising. Vaginoplasty is not always necessary, but is usually an important step into gender transition. In France, surgical techniques' gold-standard is the peno-scrotal inversion vaginoplasty, which consists in the creation of a neo-vagina with peno-scrotal skin graft. Genital, perineum and pelvic anatomy is modified, without knowing in advance about functional and aesthetic results. MRI is the best way to assess soft tissue anatomy in the pelvis. Though, only few studies have assessed pre and post-operative imaging in patients undergoing vaginoplasty, and none have been prospective, neither have assessed the risk of rectocele. The issue is legitimate, because the surgery weakens elements of pelvic fixity, and fixity issues can appear secondarily.

MtF transgender patients operated for a vaginoplasty are undergoing static and dynamic MRI before the surgery, at 6 and at 24 post-operative months. We look after the appearance of a rectocele and it's evolution in time, as criteria for the assessment of pelvic fixity.

Follow-up is composed of several consultations including post-operative MRI, but also clinical measures, census of post-operative issues, and questionnaires for the assessment of secondary objectives.

02

Conditions studied

  • Transgenderism

Browse trials for

Keywords

  • MtF, transgender, vaginoplasty, penoscrotal inversion, MRI
03

In context

Transsexualism

54 studies on the registry are indexed under Transsexualism; 18 are open to participants now.

This study's planned enrollment of 50 is above the median of 44 across 26 interventional studies indexed under Transsexualism.

Browse Transsexualism studies →

Lead sponsor

University Hospital, Limoges is the lead sponsor of 265 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years old
  • Patient admitted in urology ward at Limoges' University Hospital for MtF sexual reassignment surgery by vaginoplasty
  • Patient affiliated or benefitting from a social security system
  • Patient free, informed, written and signed consent

Exclusion criteria

Exclusion Criteria:

  • Patient admitted for vulvoplasty surgery
  • Patient admitted for second vaginoplasty surgical gesture
  • of realizing an MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Anatomy reorganization after vaginoplasty in transgender women (MtF)

    The research consists of adding to the usual MtF transgender patient undergoing vaginoplasty care course, static and dynamic perineo-pelvic MRI before, and at 6 and 24 months. The aim is to assess perineo-pelvic static's evolution, based on the appearance of a rectocele.

    Diagnostic Test: Static and dynamic perineo-pelvic MRI

Interventions

  • Diagnostic testStatic and dynamic perineo-pelvic MRI

    Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.

06

What researchers measure

Primary outcomes

  1. Measurement comparison of the rectal bulge's size and classification

    Comparison and classification by pre-operative and post-operative MRI

    Time frame: 6 months and 24 months

Secondary outcomes

  1. Rectocele

    Describe the rectocele's mean size and it's progress

    Time frame: 6 months and 24 months

  2. Rectocele

    Describe the rectocele size's progress by class

    Time frame: 6 months and 24 months

  3. Reproducibility in the rectocele's measurement

    Evaluate intra and inter-operator reproducibility in the rectocele's measurement

    Time frame: 6 months and 24 months

  4. Symptomatology pelvic fixity

    Evaluate correlation between symptomatology and the rectocele assessment

    Time frame: 6 months and 24 months

  5. Factors pelvic fixity

    Evaluate correlation between factors and the rectocele assessment

    Time frame: 6 months and 24 months

  6. Skin-graft's neo-vagina's sizes

    Evaluate correlation between the skin-graft's size in cm² and the neo-vagina's sizes (lenght, width) in cm

    Time frame: 6 months and 24 months

  7. Imaging measures

    Evaluate modifications of imaging measures size in cm² and the neo-vagina's sizes (lenght, width) in cm

    Time frame: 6 months and 24 months

  8. Urinary quality

    Evaluate evolution of unrinary quality of life with Urinary Symptom Profile (USP) score, from 0 (best) to 39 (worst)

    Time frame: 6 months and 24 months

  9. Self-imaging

    Evaluate evolution of self-imaging with Body Image (BI-1) score, from 30 (no change) to 150 (change) ; and Female Genital Self-Image Scale (FGSIS) score, from 7 (worst) to 28 (best)

    Time frame: 6 months and 24 months

  10. Sexual quality

    Evaluate evolution of sexual quality of life with Operated Male-to-Female Sexual Function Index (OmtFSFI) score, from 18 (best) to 72 (worst)

    Time frame: 6 months and 24 months

  11. Post-operative issues

    Epidemiologic census of post-operative issues

    Time frame: Instantly, 6 months and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2025, 24 months after the start.

Of 14 interventional studies with no phase under Transsexualism, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 36. This study's planned 24 months is close to that.

Transsexualism covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Oct 23, 2023
StartActual
Sep 8, 2023
Primary completionEst.
Sep 8, 2025
CompletionEst.
Jul 15, 2026
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06093724
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Sep 8, 2023
Primary completion
Sep 8, 2025 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
Jul 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion